1. Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
   Jason J. Zoeller et al, 2019, Molecular Cancer Therapeutics CrossRef
2. Evolution of low HER2 expression between early and advanced-stage breast cancer
   Paolo Tarantino et al, 2022, European Journal of Cancer CrossRef
3. The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
   Eda Caliskan Yildirim et al, 2023, The Breast CrossRef
4. Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study
   T. Önder et al, 2024, International Journal of Clinical Oncology CrossRef
5. Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo
   Wei Wang et al, 2019, BioMed Research International CrossRef
6. Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
   Katrin Almstedt et al, 2023, Cancers CrossRef
7. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer
   Tatjana Geukens et al, 2023, European Journal of Cancer CrossRef
8. Update on HER2 expression in breast cancer
   Melissa Krystel-Whittemore et al, 2022, Diagnostic Histopathology CrossRef
9. Wilms’ Tumor 1 (WT1)-Targeted Cancer Vaccines To Extend Survival for Patients with Pancreatic Cancer
   Shigeo Koido et al, 2016, Immunotherapy CrossRef
10. Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression
    Qin Shi et al, 2023, BMC Cancer CrossRef
11. HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
    Mengyuan Cai et al, 2023, BMC Cancer CrossRef
12. Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers
    Anthony Bergeron et al, 2023, British Journal of Cancer CrossRef
13. Dendritic-Tumor Fusion Cell-Based Cancer Vaccines
    Shigeo Koido, 2016, International Journal of Molecular Sciences CrossRef
14. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer
    Juan Jin et al, 2023, Journal of Translational Medicine CrossRef
15. An amplification strategy for detecting HER2 with a quasi-targeted proteomics approach coupled with aptamer-triggered hybridization chain reaction
    Jingjing Bao et al, 2020, Talanta CrossRef
16. Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
    Gary Tozbikian et al, 2024, Archives of Pathology & Laboratory Medicine CrossRef
17. HER2-Low Breast Cancer: Now and in the Future
    Sora Kang et al, 2024, Cancer Research and Treatment CrossRef
18. Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and HER2 Amplification
    Matthew J Burky et al, 2020, Breast Cancer: Basic and Clinical Research CrossRef
19. HER2-Low Breast Cancer: Pathological and Clinical Landscape
    Paolo Tarantino et al, 2020, Journal of Clinical Oncology CrossRef